Filing Details
- Accession Number:
- 0001209191-19-007775
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-06 16:50:50
- Reporting Period:
- 2019-02-04
- Accepted Time:
- 2019-02-06 16:50:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp\Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-02-04 | 4,250 | $109.41 | 51,002 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-02-04 | 2,155 | $91.05 | 53,157 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-02-04 | 1,554 | $86.52 | 54,711 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-02-04 | 1,400 | $184.81 | 53,311 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-02-04 | 12,565 | $186.10 | 40,746 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-02-04 | 4,044 | $186.84 | 36,702 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-02-04 | 300 | $188.07 | 36,402 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2019-02-04 | 4,250 | $0.00 | 4,250 | $109.14 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2019-02-04 | 2,155 | $0.00 | 2,155 | $91.05 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2019-02-04 | 1,554 | $0.00 | 1,554 | $86.52 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2025-02-02 | No | 4 | M | Direct | |
| 8,621 | 2026-02-01 | No | 4 | M | Direct | |
| 12,426 | 2027-02-02 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $184.81(range $184.50 to $185.50).
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $186.10 (range $185.55 to $186.50).
- Open market sales reported on this line occurred at a weighted average price of $186.84 (range $186.52 to $187.33).
- Open market sales reported on this line occurred at a weighted average price of $188.07(range $187.51 to $188.35).
- The option vests in 16 quarterly installments from 02/03/2015.
- The option vests in 16 quarterly installments from 02/02/2016.
- The option vests in 16 quarterly installments from 02/03/2017.
Billionaire Hedge Funds
